title: Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2).
abstract: Involvement of the contact system of coagulation in the pathogenesis of various inflammatory diseases is suggested by reduced plasma levels of factor XII (Hageman factor) and prekallikrein generally considered to result from activation of the contact system. However, in many of these diseases patients develop an acute-phase response and, therefore, an alternative explanation for the decreased levels of factor XII could be the downregulation of factor XII gene expression in the liver as described for negative acute-phase proteins. We report here that interleukin-6 (IL-6), the principal cytokine mediating the synthesis of most acute-phase proteins in the liver, downregulates the production of factor XII by the human hepatoma cell line HepG2 by up to 75%. The decrease in protein secretion correlated with an equivalent decrease of factor XII mRNA likely indicating a pretranslational control of factor XII gene expression by IL-6. Downregulation of factor XII production by IL-6 in vitro parallelled that of transthyretin, a known negative acute-phase protein. Moreover, we show that, in patients developing an acute-phase response after immunotherapy with IL-2, plasma levels of factor XII correlate (r = .76, P < .0001) with those of transthyretin. Taken together, these results suggest that factor XII behaves as a negative acute-phase protein.
authors.affiliation: Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, and University of Amsterdam.
authors.forename: F
authors.initials: F
authors.lastname: Citarella
authors.forename: A
authors.initials: A
authors.lastname: Felici
authors.forename: M
authors.initials: M
authors.lastname: Brouwer
authors.forename: J
authors.initials: J
authors.lastname: Wagstaff
authors.forename: A
authors.initials: A
authors.lastname: Fantoni
authors.forename: C E
authors.initials: CE
authors.lastname: Hack
mesh_terms: D000210:Acute-Phase Reaction; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000628:therapy; D015536:Down-Regulation / Q000187:drug effects*; D005174:Factor XII / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use; D015850:Interleukin-6 / Q000494:pharmacology*; D007680:Kidney Neoplasms / Q000378:metabolism / Q000628:therapy; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008545:Melanoma / Q000378:metabolism / Q000628:therapy; D011228:Prealbumin / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2; D015850:Interleukin-6; D011228:Prealbumin; D012333:RNA, Messenger; D005174:Factor XII